Epigenetic regulation of glucose transporters in non-small cell lung cancer

Cancers

Volumn 3, Issue 2, 2011, Pages 1550-1565

  O'Byrne, Kenneth J ^a   Baird, Anne Marie ^a   Kilmartin, Lisa ^a   Leonard, Jennifer ^a   Sacevich, Calen ^a   Gray, Steven G ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Epigenetics; Glucose transporter; NSCLC

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ADENOSINE TRIPHOSPHATE; DEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; HISTONE DEACETYLASE INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; INSULIN; INSULIN RECEPTOR; MESSENGER RNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; TRANSCRIPTION FACTOR CTCF; TRIBUTYRATE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; BIOINFORMATICS; BRONCHUS MUCOSA; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL HYPOXIA; CELL TRANSFORMATION; CHEMOSENSITIVITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG TARGETING; ENERGY CONSUMPTION; EPITHELIUM CELL; GENETIC REGULATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; KIDNEY CELL; LIVER CELL; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MUSCLE CELL; POSITRON EMISSION TOMOGRAPHY; PROADIPOCYTE; PROMOTER REGION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

EID: 79959749854     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3021550     Document Type: Article

References (42)

1. Garber, K. Energy deregulation: licensing tumors to grow. Science 2006, 312, 1158-1159. 2.
2. Ganapathy, V.; Thangaraju, M.; Prasad, P.D. Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009, 121, 29-40.
3. Busk, M.; Horsman, M.R.; Kristjansen, P.E.; van der Kogel, A.J.; Bussink, J.; Overgaard, J. Aerobic glycolysis in cancers: Implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int. J. Cancer 2008, 122, 2726-2734.
4. Uldry, M.; Thorens, B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 2004, 447, 480-489.
5. Simpson, I.A.; Dwyer, D.; Malide, D.; Moley, K.H.; Travis, A.; Vannucci, S.J. The facilitative glucose transporter GLUT-3: 20 years of distinction. Am. J. Physiol. Endocrinol Metab. 2008, 295, E242-E253.
6. Brown, R.S.; Leung, J.Y.; Kison, P.V.; Zasadny, K.R.; Flint, A.; Wahl, R.L. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J. Nucl. Med. 1999, 40, 556-565.
7. Wood, I.S.; Trayhurn, P. Glucose transporters (GLUT and SGLT): Expanded families of sugar transport proteins. Br. J. Nutr. 2003, 89, 3-9.
8. Birnbaum, M.J. Identification of a novel gene encoding an insulin-responsive glucose transporter protein. Cell 1989, 57, 305-315.
9. Garvey, W.T.; Maianu, L.; Zhu, J.H.; Brechtel-Hook, G.; Wallace, P.; Baron, A.D. Evidence for defects in the trafficking and translocation of GLUT-4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J. Clin. Invest. 1998, 101, 2377-2386.
10. Devaskar, S.U.; deMello, D.E. Cell-specific localization of glucose transporter proteins in mammalian lung. J. Clin. Endocrinol. Metab. 1996, 81, 4373-4378.
11. Ito, T.; Noguchi, Y.; Udaka, N.; Kitamura, H.; Satoh, S. Glucose transporter expression in developing fetal lungs and lung neoplasms. Histol. Histopathol. 1999, 14, 895-904.
12. Ito, T.; Noguchi, Y.; Satoh, S.; Hayashi, H.; Inayama, Y.; Kitamura, H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod. Pathol. 1998, 11, 437-443.
13. Muller-Tidow, C.; Diederichs, S.; Bulk, E.; Pohle, T.; Steffen, B.; Schwable, J.; Plewka, S.; Thomas, M.; Metzger, R.; Schneider, P.M.; Brandts, C.H.; Berdel, W.E.; Serve, H. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res. 2005, 65, 1778-1782.
14. Lehrer, S. Inhaled insulin for the early detection of lung cancer. Med. Hypotheses 2008, 71, 615-616.
15. Lawless, M.W.; Norris, S.; O'Byrne, K.J.; Gray, S.G. Targeting histone deacetylases for the treatment of disease. J. Cell. Mol. Med. 2009, 13, 826-852.
16. Raychaudhuri, N.; Raychaudhuri, S.; Thamotharan, M.; Devaskar, S.U. Histone code modifications repress glucose transporter 4 expression in the intrauterine growth-restricted offspring. J. Biol. Chem. 2008, 283, 13611-13626.
17. Gray, S.G.; Qian, C.N.; Furge, K.; Guo, X.; Teh, B.T. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int. J. Oncol. 2004, 24, 773-795.
18. Berger, S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447, 407-412.
19. Sims, R.J., 3rd; Millhouse, S.; Chen, C.F.; Lewis, B.A.; Erdjument-Bromage, H.; Tempst, P.; Manley, J.L.; Reinberg, D. Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol. Cell. 2007, 28, 665-676.
20. Pinskaya, M.; Morillon, A. Histone H3 lysine 4 di-methylation: A novel mark for transcriptional fidelity? Epigenetics 2009, 4, 302-306.
21. Pekowska, A.; Benoukraf, T.; Ferrier, P.; Spicuglia, S. A unique H3K4me2 profile marks tissuespecific gene regulation. Genome Res. 2010, 20,1493-502.
22. Black, J.C.; Whetstine, J.R. Chromatin landscape: Methylation beyond transcription. Epigenetics 2011, 6, 9-15.
23. Phillips, J.E.; Corces, V.G. CTCF: master weaver of the genome. Cell 2009, 137, 1194-1211.
24. Barski, A.; Cuddapah, S.; Cui, K.; Roh, T.Y.; Schones, D.E.; Wang, Z.; Wei, G.; Chepelev, I.; Zhao, K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129, 823-837.
25. Liu, M.L.; Olson, A.L.; Edgington, N.P.; Moye-Rowley, W.S.; Pessin, J.E. Myocyte enhancer factor 2 (MEF2) binding site is essential for C2C12 myotube-specific expression of the rat GLUT-4/muscle-adipose facilitative glucose transporter gene. J. Biol. Chem. 1994, 269, 28514-28521.
26. Mukwevho, E.; Kohn, T.A.; Lang, D.; Nyatia, E.; Smith, J.; Ojuka, E.O. Caffeine induces hyperacetylation of histones at the MEF2 site on the Glut-4 promoter and increases MEF2A binding to the site via a CaMK-dependent mechanism. Am. J. Physiol. Endocrinol. Metab. 2008, 294, E582-E588.
27. Sparling, D.P.; Griesel, B.A.; Weems, J.; Olson, A.L. GLUT-4 enhancer factor (GEF) interacts with MEF2A and HDAC5 to regulate the GLUT-4 promoter in adipocytes. J. Biol. Chem. 2008, 283, 7429-7437.
28. Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8, 915-928.
29. Gray, S.G.; Stenfeldt Mathiasen, I.; De Meyts, P. The insulin-like growth factors and insulinsignalling systems: An appealing target for breast cancer therapy? Horm. Metab. Res. 2003, 35, 857-871.
30. Gridelli, C.; Rossi, A.; Bareschino, M.A.; Schettino, C.; Sacco, P.C.; Maione, P. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin. Investig. Drugs 2010, 19, 631-639.
31. Lawless, M.W.; O'Byrne, K.J.; Gray, S.G. Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones? Curr. Diabetes Rev. 2009, 5, 201-209.
32. Lawless, M.W.; Norris, S.; O'Byrne, K.J.; Gray, S.G. Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders. Endocr. Metab. Immune Disord. Drug Targets 2009, 9, 84-107.
33. Gray, S.G.; De Meyts, P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes. Metab. Res. Rev. 2005, 21, 416-433.
34. Inamochi, Y.; Mochizuki, K.; Osaki, A.; Ishii, T.; Nakayama, T.; Goda, T. Histone H3 methylation at lysine 4 on the SLC2A5 gene in intestinal Caco-2 cells is involved in SLC2A5 expression. Biochem. Biophys. Res. Commun. 2010, 392, 16-21.
35. Wardell, S.E.; Ilkayeva, O.R.; Wieman, H.L.; Frigo, D.E.; Rathmell, J.C.; Newgard, C.B.; McDonnell, D.P. Glucose metabolism as a target of histone deacetylase inhibitors. Mol. Endocrinol. 2009, 23, 388-401.
36. Dwarakanath, B.S. Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2- deoxy-D-glucose in vitro. J. Cancer Res. Ther. 2009, 5(Suppl 1), S27-S31.
37. Farooque, A.; Afrin, F.; Adhikari, J.S.; Dwarakanath, B.S. Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-D-glucose. J. Cancer Res. Ther. 2009, 5 (Suppl 1), S32-35.
38. Gould, G.W.; Holman, G.D. The glucose transporter family: structure, function and tissue-specific expression. Biochem. J. 1993, 295 (Pt 2), 329-341.
39. Warnken, M.; Reitzenstein, U.; Sommer, A.; Fuhrmann, M.; Mayer, P.; Enzmann, H.; Juergens, U.R.; Racke, K. Characterization of proliferative effects of insulin, insulin analogues and insulinlike growth factor-1 (IGF-1) in human lung fibroblasts. Naunyn. Schmiedebergs. Arch. Pharmacol. 2010, 382, 511-524.
40. Papagianni, M.; Hatziefthimiou, A.; Chachami, G.; Gourgoulianis, K.; Molyvdas, P.A.; Paraskeva, E. Inhaled insulin does not trigger lung inflammation and airway remodelling. Eur. Respir. J. 2009, 33, 444-445.
41. Wabitsch, M.; Brenner, R.E.; Melzner, I.; Braun, M.; Moller, P.; Heinze, E.; Debatin, K.M.; Hauner, H. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int. J. Obes. Relat. Metab. Disord. 2001, 25, 8-15.
42. Jiang, C.; Xuan, Z.; Zhao, F.; Zhang, M.Q. TRED: A transcriptional regulatory element database, new entries and other development. Nucleic Acids Res. 2007, 35, D137-D140.